Abstract:11553 Background: Anthracycline plus ifosfamide is the standard first line treatment regime for advanced soft tissue sarcoma (STS). Anlotinib, a multikinase angiogenesis inhibitor, has evolved as a standard second line treatment option in Chinese advanced STS patients. This study was performed to evaluate the efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in the first line treatment of patients with advanced STS. Methods: This prospective, open-label, single-arm, phase 2 trial was conducted in Shandong Cancer Hospital and Institute (ChiCTR2100054711). The key inclusion criteria included: (a) age was 18-70 years; (b) ECOG performance state of 0-1; (c) histologically confirmed high-grade STS; (d) unresectable or metastatic STS; (e) previously untreated, and sensitive to chemotherapy; (f) having measurable lesions according to RECIST 1.1. All patients received up to 6 cycles of anlotinib (12 mg QD on day1-14, 21 days per cycle) combined with anthracycline (epirubicin 40mg/m 2 /d on day 1-2, 21 days per cycle; or liposomal doxorubicin 30mg/m 2 /d on day 1, 21 days per cycle) and ifosfamide (2g/m 2 /d on day 1-3, 21 days per cycle) followed by anlotinib maintenance until disease progression, unacceptable toxicity or death. Pegylated recombinant human granulocyte colony-stimulating factor was administered following chemotherapy. The primary endpoint was objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), and adverse effect (AE). Results: From December 2021 to December 2022, 31 patients (median [range] age, 53 [18-69] years; 20 [64.5%] male) were enrolled. 29 were evaluable for objective response, and the ORR and DCR were 31.03% (95%CI, 17.28-49.23%) and 82.76% (95%CI, 65.45-92.4%), respectively. With a median follow-up duration of 6.3 months (range, 0.8–14.0), the median PFS for all 31 patients was 6.9 months (95% CI, 2.62-11.17). The median OS was not reached. Treatment-related AEs of any grade occurred in all patients. The most common AEs included nausea/vomiting (88.46%), anemia (23.08%), leukopenia (19.23%), venous thrombosis (15.38%), hand-foot syndrome (11.54%) and elevated alanine aminotransferase or aspartate aminotransferase (11.54%). The most frequent ≥ grade 3 AEs were leukopenia (11.54%) and thrombocytopenia (7.69%). 2 serious AEs (1 left heart failure and 1 intestinal obstruction) were recorded. No treatment-related death occurred. Conclusions: This study suggested that anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance demonstrated encouraging efficacy with a manageable safety profile in the first line treatment of patients with advanced STS. Clinical trial information: ChiCTR2100054711 .

Supplementary Data 1 from First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: an Open-Label, Single-Arm, Phase 2 Clinical Trial

Table S1 from Anlotinib Plus Epirubicin Followed by Anlotinib Maintenance As First-line Treatment for Advanced Soft-tissue Sarcoma: an Open-label, Single-arm, Phase II Trial

First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: an Open-Label, Single-Arm, Phase 2 Clinical Trial.

A phase II study of anlotinib in the first-line treatment of locally advanced or metastatic soft-tissue sarcoma: Updated results.

First Line Anlotinib Plus Liposomal Doxorubicin for Locally Advanced or Metastatic Soft Tissue Sarcoma: A Prospective, Single-Arm Trial

Efficacy and Safety of Anlotinib in Advanced Soft Tissue Sarcoma: Results from One of Multi-Centers in a Phase IIB Trial (ALTER0203).

Anlotinib hydrochloride capsules for advanced soft tissue sarcoma: single-center data analysis of a stageⅡmulticenter clinical trial

Phase II Study of Anlotinib for Treatment of Advanced Soft Tissues Sarcomas.

P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial

Supplementary Figure from Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma

Efficacy and Safety of Anlotinib Plus TQB2450 in Patients with Advanced Soft Tissue Sarcoma: A Multicenter, Single Armed, Phase 1b Trial.

Efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in advanced soft tissue sarcoma: A single-arm, phase 2 trial.

Anlotinib plus epirubicin followed by anlotinib maintenance as first-line treatment for advanced soft tissue sarcoma: an open-label, single-arm, phase 2 trial

Supplementary Table S5 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: an Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001

Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

Anlotinib Plus Epirubicin Followed by Anlotinib Maintenance As First-line Treatment for Advanced Soft-tissue Sarcoma: an Open-label, Single-arm, Phase II Trial

Anlotinib Versus Placebo As Adjuvant Therapy for Completely Resected High-Grade Soft Tissue Sarcomas: Interim Results of a Phase 2, Double-Blinded, Randomized Controlled Trial.

Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)

Anlotinib for Metastasis Soft Tissue Sarcoma: A Randomized, Double-Blind, Placebo-Controlled and Multi-Centered Clinical Trial.